ArticleNPJ precision oncology2026

Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study.

Kevin C Flanagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.